Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma

Blood

Volumn 104, Issue 1, 2004, Pages 227-236

  Forero, Andres ^a   Weiden, Paul L ^b   Vose, Julie M ^b   Knox, Susan J ^b   LoBuglio, Albert F ^b   Hankins, Jordan ^b   Goris, Michael L ^b   Picozzi, Vincent J ^b   Axworthy, Don B ^b   Breitz, Hazel B ^b   Sims, Robert B ^b   Ghalie, Richard G ^b   Shen, Sui ^b   Meredith, Ruby F ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ANTINEOPLASTIC AGENT; BIOTIN; CD20 ANTIBODY; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; HYBRID PROTEIN; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; INDIUM 111; METHOTREXATE; METHYLPREDNISOLONE; MITOGUAZONE; MITOXANTRONE; PREDNISONE; RHENIUM 186; RITUXIMAB; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; STREPTAVIDIN; TOSITUMOMAB I 131; VINCRISTINE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; ASTHENIA; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CHOLELITHIASIS; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DOSIMETRY; DRUG MEGADOSE; DRUG SAFETY; DYSPEPSIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; FOLLICULAR LYMPHOMA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATURIA; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; LYMPHOMA; MALE; MANTLE CELL LYMPHOMA; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; PRETARGETED RADIOIMMUNOTHERAPY; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; RASH; SCINTILLATION CAMERA; SERUM SICKNESS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 3042796950     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-09-3284     Document Type: Article

References (29)

1. Nadler LM, Stashenko P, Hardy R, et al. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res. 1980;40:3147-3154.
2. Miller RA, Maloney DG, Warnke R, Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med. 1982;306:517-522.
3. McLaughlin P, Grillo-Lopez AJ, Link, BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed Indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825-2833.
4. McLaughlin P, Grillo-Lopez AJ, Maloney D, et al. Efficacy controls in long-term follow-up of patients treated with Rituximab for relapsed or refractory, low-grade or follicular NHL. Blood. 1998;92(suppl 1): 414a-415a.
5. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:2453-2463.
6. Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine 1131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2001;19:3918-3928.
7. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:3262-3269.
8. Horning SJ, Lucas JB, Younes A, et al. Iodine-131 tositumomab for non-Hodgkin's lymphoma (NHL) patients who progressed after treatment with rituximab: results of a multicenter phase II study [abstract]. Blood. 2000;96:508a,
9. Kaminski MS, Estec J, Tuck M, et al. Iodine 131 tositumomab therapy for previously untreated follicular lymphoma [abstract]. Proc Am Soc Clin Oncol. 2000;19:11a.
10. Langmuir VK. Radioimmunotherapy: clinical results and dosimetric considerations. Intl J Rad Appl Instrum B. 1992;19:213-225.
11. Fritzberg AR. Biorecognition of antibodies in vivo: potential in drug targeting. J Mol Recognit. 1996;9:309-315.
12. Liu SY, Eary JF, Petersdorf SH, et al. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131- labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol. 1998;16:3270-3278.
13. Goodwin DA, Meares CF, McCall MJ, McTigue M, Chaovapong W. Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens. J Nucl Med. 1988;29(pt 2): 226-234.
14. Paganelli G, Riva P, Deleide G, et al. In vivo labeling of biotinylated monoclonal antibodies by radioactive avidin: a strategy to increase tumor localization. Intl J Cancer Suppl. 1988;2:121-125.
15. Saga T, Weinstein JN, Jeong JM, et al. Two-step targeting of experimental lung metastases with biotinylated antibody and radiolabeled streptavidin. Cancer Res. 1994;54:2160-2165.
16. Goodwin DA, Meares CF, Osen M. Biological properties of biotin-chelate conjugates for pretargeted diagnosis and therapy with avidin/biotin system. J Nucl Med. 1998;39:1813-1818.
17. Press OW, Corcoran M, Subbiah K, et al. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. Blood. 2001;98:2535-2543.
18. Axworthy DB, Reno JM, Hylarides MD, et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci U S A. 2000;97:1802-1807.
19. 90Y-DOTA-biotin. J Nucl Med. 2000;41:131-140.
20. 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin. Cancer Biother Radiopharm. 1999;14:381-395.
21. Knox SJ, Goris ML, Tempero M, et al. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin Cancer Res. 2000;6:406-414.
22. Weiden PL, Small EJ, Hudes GR, et al. A phase II trial of pretargeted radioimmunotherapy (PRIT) in patients with metastatic hormone resistant prostate cancer (HRPC) [abstract]. J Clin Oncol. 1999;18:313a.
23. Weiden PL, Breitz HB. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL). Critical Reviews Onc-Hem. 2001;40:37-51.
24. Schultz J, Lin Y, Sanderson J, et al. A tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy. Cancer Res. 2000;60:6663-6669.
25. Theodore LJ, Axworthy DB. Cluster clearing agents. PCT Application International, 1997. Publication no. WO 97/46098.
26. Weiden P. Pretargeted radioimmunotherapy (PRIT) using an antibody-streptavidin fusion protein in non-Hodgkin's lymphoma. Leuk Lymphoma. 2002;43:1971-1973.
27. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol. 1999;17:1244.
28. Axworthy DB, Theodore LJ, Gustavson LM, Reno JM, inventors, Biotinidase resistant biotin-DOTA conjugates. US patent 5 955 605. September 21, 1999.
29. Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 1996;37:538-546.